Clinical Trial

A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer

Study acronym: DuraSTAR
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is conducted in adults with rectal cancer that has a certain genetic type. The main goal is to find out whether a longer treatment period with dostarlimab can help more participants have a complete response to treatment and avoid standard treatments like chemotherapy, radiation treatment, or surgery. Scans and endoscopy tests will be conducted to see if the tumor disappears and how long the cancer stays under control. The study will also collect information on side effects and health outcomes after dostarlimab.
Trial Details
NCT Number NCT07740720
Lead Sponsor GlaxoSmithKline
Conditions Neoplasms, Rectal
Enrollment 90 participants
Start Date 2026-09-17
Primary Completion 2029-12-12 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-03